Abstract: Objective To retrospectively evaluate the clinical efficacy of Qingfei Paidu decoction in the treatment of coronavirus disease 2019(COVID-19)and to explore the possible mechanism. Methods A total of 89 COVID-19 patiests whose date of discharge ranged from Feb. 10 to Apr. 1, 2020 were selected in the infection ward of the East Hospital of Renmin Hospital of Wuhan University. According to whether Qingfei Paidu decoction was used, 89 cases were divided into basic treatment group(n=46)and combined treatment group(n=43). The paitents in basic treatment group were only given western medicine treatment, while those in combined treatment group were treated with modified Qingfei Paidu decoction on the basis of western medicine treatment plan. The changes of blood routine, C reactive protein(CRP), interleukin-6(IL-6), cellular immunity, biochemical series and coagulation series were compared between the two groups before and after treatment. The changes of lung CT, the time of nucleic acid turning negative, and the patients hospitalization time were collected. A pairwise or non-paired t test was used to compare numerical data with normal distribution; the counting data were described by relative numbers, and the differences between groups were tested by chi-square test. Results (1) After the treatment, the expression levels of neutrophil ratio(NEU%), CRP, IL-6, creatine kinase(CK), lactate dehydrogenase(LDH), fibrinogen(Fib)and fibrinogen degradation product(FDP)were decreased in the two groups(P<0.05); the counts of lymphocyte ratio(LYM%), CD3, CD4 and CD8 T cells were significantly increased in the two groups(P<0.05); the levels of serum creatinine(SCr)and D-dimer(DD)were decreased while the estimated glomerular filtration rate(eGFR)was increased in the combined treatment group(P<0.05). (2) Compared with the basic treatment group, the difference of CD3 and IL-6 before and after treatment in the combination treatment group was statistically significant(P<0.05). There was no difference in the degree of improvement of chest CT between the two groups. The length of hospital stay in the combined treatment group was shorter than that in the basic treatment group(P<0.01), and the nucleic acid conversion time was shorter without statistical difference. Conclusion (1) The level of inflammation is reduced, cellular immunity is enhanced, renal function is improved, and hypercoagulability is reduced in both the basic treatment group and combined treatment group. (2) Compared with the basic treatment group, modified Qingfei Paidu decoction can significantly reduce the level of IL-6 and increase the level of CD3 of COVID-19 patients. The treatment of integrated traditional Chinese medicine and western medicine can significantly inhibit the inflammatory reaction, enhance the bodys immunity, and shorten the length of hospitalization and nucleic acid negative time, which help to get a better clinical efficacy.

Key words: Modified Qingfei Paidu decoction, Coronavirus disease 2019, Clinical study, Inflammatory factors, Cell-mediated immunity